Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Stemline Therapeutics Inc Prices $60 Million Public Offering Of Common Stock


Thursday, 16 May 2013 05:47pm EDT 

Stemline Therapeutics Inc announced that the pricing of an underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $14.50 per share. Stemline has granted the underwriters a 30-day option to purchase up to 620,689 additional shares of common stock from Stemline. The gross proceeds to Stemline from the public offering are expected to be $60.0 million, before underwriting discounts and commissions and other estimated offering expenses. Stemline intends to use the net proceeds from the public offering to fund the clinical development of SL-401 and SL-701 and other general corporate purposes. Jefferies LLC and Aegis Capital Corp. are acting as joint book-running managers for the offering. Roth Capital Partners is acting as co-lead manager for the offering. 

Company Quote

13.21
0.47 +3.69%
20 Oct 2014